Is Iteos Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: ITOS) stock is to Buy ITOS stock.
Out of 1 analyst, 0 (0%) are recommending ITOS as a Strong Buy, 1 (100%) are recommending ITOS as a Buy, 0 (0%) are recommending ITOS as a Hold, 0 (0%) are recommending ITOS as a Sell, and 0 (0%) are recommending ITOS as a Strong Sell.
What is ITOS's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: ITOS) forecast ROE is N/A, which is considered weak.
What is ITOS's Price Target?
According to 1 Wall Street analyst that have issued a 1 year ITOS price target, the average ITOS price target is $44.00, with the highest ITOS stock price forecast at $44.00 and the lowest ITOS stock price forecast at $44.00.
The Wall Street analyst predicted that Iteos Therapeutics's share price could reach $44.00 by Aug 9, 2024. The average Iteos Therapeutics stock price prediction forecasts a potential upside of 287.32% from the current ITOS share price of $11.36.
What is ITOS's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: ITOS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.1%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.